Schedule of Segment Reporting Information, by Segment |
The tables below present segment information reconciled to total Company financial results, with segment operating income or loss including gross profit less direct research and development expenses and direct selling expenses as well as any litigation settlements, to the extent specifically identified by segment (in thousands): | | | | | | | | | | | | | | | | | | Year Ended December 31, 2018 | | Generics | | Specialty | | Corporate and Other | | Total Company | Net revenue | | $ | 1,439,031 |
| | $ | 223,960 |
| | $ | — |
| | $ | 1,662,991 |
| Cost of goods sold | | 842,996 |
| | 103,592 |
| | — |
| | 946,588 |
| Gross profit | | 596,035 |
| | 120,368 |
| | — |
| | 716,403 |
| Selling, general and administrative | | 68,426 |
| | 49,465 |
| | 112,544 |
| | 230,435 |
| Research and development | | 183,412 |
| | 10,778 |
| | — |
| | 194,190 |
| In-process research and development impairment charges
| | 39,259 |
| | — |
| | — |
| | 39,259 |
| Acquisition, transaction-related and integration expenses | | 114,622 |
| | — |
| | 107,196 |
| | 221,818 |
| Restructuring and asset-related charges | | 33,943 |
| | 4,076 |
| | 18,394 |
| | 56,413 |
| Intellectual property legal development expenses | | 15,772 |
| | 489 |
| | — |
| | 16,261 |
| Legal settlement gains | | (22,300 | ) | | — |
| | — |
| | (22,300 | ) | Operating income (loss) | | $ | 162,901 |
| | $ | 55,560 |
| | $ | (238,134 | ) | | $ | (19,673 | ) |
| | | | | | | | | | | | | | | | | | Year Ended December 31, 2017 | | Generics | | Specialty | | Corporate and Other | | Total Company | Net revenue | | $ | 1,033,654 |
| | $ | — |
| | $ | — |
| | $ | 1,033,654 |
| Cost of goods sold | | 507,476 |
| | — |
| | — |
| | 507,476 |
| Gross profit | | 526,178 |
| | — |
| | — |
| | 526,178 |
| Selling, general and administrative | | 56,050 |
| | — |
| | 52,996 |
| | 109,046 |
| Research and development | | 171,420 |
| | — |
| | — |
| | 171,420 |
| Intellectual property legal development expenses | | 20,518 |
| | — |
| | — |
| | 20,518 |
| Legal settlement gains
| | (29,312 | ) | | — |
| | — |
| | (29,312 | ) | Acquisition and transaction-related expenses | | — |
| | — |
| | 9,403 |
| | 9,403 |
| Operating income (loss) | | $ | 307,502 |
| | $ | — |
| | $ | (62,399 | ) | | $ | 245,103 |
|
| | | | | | | | | | | | | | | | | | Year Ended December 31, 2016 | | Generics | | Specialty | | Corporate and Other | | Total Company | Net revenue | | $ | 1,018,225 |
| | $ | — |
| | $ | — |
| | $ | 1,018,225 |
| Cost of goods sold | | 420,770 |
| | — |
| | — |
| | 420,770 |
| Gross profit | | 597,455 |
| | — |
| | — |
| | 597,455 |
| Selling, general and administrative | | 69,540 |
| | — |
| | 49,217 |
| | 118,757 |
| Research and development | | 179,019 |
| | — |
| | — |
| | 179,019 |
| Intellectual property legal development expenses | | 25,728 |
| | — |
| | — |
| | 25,728 |
| Legal settlement gains | | (11,000 | ) | | — |
| | — |
| | (11,000 | ) | Acquisition and transaction-related expenses | | — |
| | — |
| | 70 |
| | 70 |
| Operating income (loss) | | $ | 334,168 |
| | $ | — |
| | $ | (49,287 | ) | | $ | 284,881 |
|
|
Schedules of Concentration of Risk |
The Company's significant product families, as determined based on net revenue, and their percentage of the Company's consolidated net revenue for each of the years ended December 31, 2018, 2017 and 2016 are set forth below (in thousands, except for percentages):
| | | | | | | | | | Segment | | Product Family | | Year Ended December 31, 2018 | | | | | $ | | % | Generics | | Yuvafem-Estradiol | | $ | 130,920 |
| | 8% | Generics | | Diclofenac Sodium Gel | | 103,131 |
| | 6% | Specialty | | Rytary® family | | 95,541 |
| | 6% | Generics | | Aspirin; Dipyridamole ER Capsul | | 78,541 |
| | 5% | Generics | | Epinephrine Auto-Injector family (generic Adrenaclick®) | | $ | 67,529 |
| | 4% |
| | | | | | | | | | Segment | | Product Family | | Year Ended December 31, 2017 | | | | | $ | | % | Generics | | Yuvafem-Estradiol | | $ | 130,480 |
| | 13% | Generics | | Diclofenac Sodium Gel | | 94,395 |
| | 9% | Generics | | Aspirin; Dipyridamole ER Capsul | | 79,674 |
| | 8% | Generics | | Oseltamivir | | 37,240 |
| | 4% | Generics | | Ranitidine
| | $ | 31,283 |
| | 3% |
| | | | | | | | | | Segment | | Product Family | | Year Ended December 31, 2016 | | | | | $ | | % | Generics | | Lidocaine | | $ | 121,832 |
| | 12% | Generics | | Diclofenac Sodium Gel | | 71,672 |
| | 7% | Generics | | Yuvafem-Estradiol | | 53,025 |
| | 5% | Generics | | Metaxalone
| | 33,698 |
| | 3% | Generics | | Metformin ER
| | $ | 33,420 |
| | 3% |
|